Photo taken from Erman Akkus/X
Feb 21, 2024, 18:13
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Tremelimumab plus durvalumab (STRIDE) in HCC:
HIMALAYA update
- 1171 patients, first line, STRIDE or Durva or sorafenib
- STRIDE versus sorafenib, OS: HR 0.78 (0.67-0.92
- durvalumab versus sorafenib, OS: HR 0.86 (0.74-1.01)
- long-term OS benefit of STRIDE versus sorafenib
- Durvalumab maintained OS noninferiority to sorafenib.”
Proceed to the article.
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56